The co-expression of PML/RAR alpha and AML1/ETO fusion genes is associated with ATRA resistance.
Abreu e Lima
Rodrigo Siqueria
RS
Baruffi
Marcelo Rozera
MR
de Lima
Ana Sílvia Gouveia
AS
de Oliveira
Fá Morato
FM
de Figueiredo-Pontes
Lorena Lôbo
LL
Tone
Luiz Gonzaga
LG
Rogatto
Sílvia Regina
SR
Falcao
Roberto Passetto
RP
Ferrari Chauffaille
Maria de Lourdes L
Mde L
Rego
Eduardo M
EM
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D050676:Core Binding Factor Alpha 2 Subunit; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D005260:Female; D006801:Humans; D007621:Karyotyping; D007951:Leukemia, Myeloid / Q000235:genetics*; D015473:Leukemia, Promyelocytic, Acute / Q000235:genetics; D008875:Middle Aged; D015514:Oncogene Proteins, Fusion / Q000235:genetics*; D000075142:RUNX1 Translocation Partner 1 Protein; D018168:Receptors, Retinoic Acid / Q000235:genetics; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors / Q000235:genetics; D014212:Tretinoin / Q000627:therapeutic use*
C107844:AML1-ETO fusion protein, human; D000970:Antineoplastic Agents; D050676:Core Binding Factor Alpha 2 Subunit; D015514:Oncogene Proteins, Fusion; C000607071:RARA protein, human; D000075142:RUNX1 Translocation Partner 1 Protein; D018168:Receptors, Retinoic Acid; D000072482:Retinoic Acid Receptor alpha; D014157:Transcription Factors; D014212:Tretinoin